<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212625</url>
  </required_header>
  <id_info>
    <org_study_id>KUGH15337</org_study_id>
    <nct_id>NCT03212625</nct_id>
  </id_info>
  <brief_title>The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction</brief_title>
  <official_title>The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and
      urea cream is typical representative. Recent study was performed prevention effect of urea
      cream for Hand-Foot Skin Reaction(HFSR) on 871 Chinese. But the study did not designed as
      placebo-control group and it had big defect in double-blinded.

      Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect
      of urea cream on Korean patient group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib is multiple tyrosine kinase inhibitor. It blocks path that such as Raf-1, Vascular
      Endothelial Growth Factor Receptor (VEGFR), Platelet-Drived Growth Factor Receptor-β
      (PDGFR-β), c-Jit, Flt-3. Sorafenib was known to increase life rate about processed
      hepatocellular carcinoma. So it is advised as standard treatment for liver cancer patient who
      has processed Barcelona Clinic Liver Cancer (BCLC) disease period C.

      Sorafenib related side effect has reported such as fatigue, diarrhea, vomit, nausea,
      pruritus, depilation, Hand-Foot Skin Reaction(HFSR). Among the symptoms, Hand-Foot Skin
      Reaction(HFSR) is the most occurrence after using sorafenib and major reason of drug dose
      de-escalation, it function as decrease anti-cancer effect of sorafenib. It is known for the
      reason of Hand-Foot Skin Reaction(HFSR) occurrence is caused by tyrosine kinase inhibitive
      action, and its characteristic symptom is known as keratocyte necrosis, dermal edema,
      parakeratosis, hyperkeratosis. The level is categorized grade 1,2,3 according to the
      severity.

      The result of meta-analysis of 24 clinical trials that contained 6000 patients, Hand-Foot
      Skin Reaction(HFSR) occured 39% of sorafenib used patients and 9% of total patients had grade
      3 Hand-Foot Skin Reaction(HFSR). But prevalence rate on hepatocellular carcinoma patients who
      used sorafenib is about 51% on Japanese, 45% on Asia-pacific patient (inclusive Korean) and
      73.6% on Chinese. Prevalence rate of Hand-Foot Skin Reaction(HFSR) is different from result
      of each study, but about 50% of sorafenib used patients has had Hand-Foot Skin Reaction(HFSR)
      generally and Asian has more higher degree of prevalence rate. Therefore, prevent and care of
      Hand-Foot Skin Reaction(HFSR) on Korean hepatocellular carcinoma patients who used sorafenib
      is required.

      Urea cream is typical representative for prevention and care of Hand-Foot Skin
      Reaction(HFSR). As stability-guaranteed drug, it is relatively cheap, locally affect and has
      used for psoriasis treatment. Also it is known for curative effacement on Hand-Foot Skin
      Reaction(HFSR) after use tyrosine kinase inhibitor such as sorafenib, sunitinib.

      Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect
      of urea cream on Korean patient group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hand-Foot Skin Reaction(HFSR) prevalence rate on each group</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>Comparison of Hand-Foot Skin Reaction(HFSR) prevalence rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival of HFSR</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>Time : From the beginning of using sorafenib to HFSR occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe HFSR prevalence rate</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>HFSR prevalence rate of grade 2 and over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of discontinuation or reduction of sorafenib</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>Prevalence of discontinuation or reduction of sorafenib due to HFSR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality Of Life (QOL)</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>Assessment of QOL related to HFSR using The Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL) scoring system. HF-QOL instrument comprises a 20-item symptom scale and an 18-item daily activity scale. Each item was scored from 0 (not at all) to 4 (always or extremely). Therefore, the range of score for HF-QoL was from 0 to 152 points. (Ref. Anderson et al. The Oncoligist 2015;20:831-838)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>Overall survival of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>Tumor response using RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other side effect</measure>
    <time_frame>12 weeks treatment</time_frame>
    <description>The occurrence rate of other side effect excluding HFSR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Urea cream 20%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>144 patients spread urea cream (urea 20%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>144 patients spread placebo cream (urea 0%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urea Cream 20%</intervention_name>
    <description>Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)</description>
    <arm_group_label>Urea cream 20%</arm_group_label>
    <other_name>Urea group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who was diagnosed with hepatocellular carcinoma, and was accompanied by
             impossible for radical treatment in disease period or do not reaction for local
             treatment, and the first time for sorafenib injection.

          -  Standard of hepatocellular carcinoma diagnosis (2014, The Korean Liver Cancer
             Association)

               1. Suitable on hepatocellular carcinoma pathologically

               2. Hepatic nodule size over 1 cm on high-risk patients(hepatitis B virus positive,
                  hepatitis C virus positive and liver cirrhosis) that identified by
                  ultrasonography : In the case of suitable on hepatocellular carcinoma on over in
                  one or two more dynamic contrast enhanced CT, dynamic contrast enhanced MRI, or
                  MRI with Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid(Gd-EOB-DTPA)

               3. Hepatic nodule size under 1 cm on high-risk patients that identified by
                  ultrasonography : serum Alpha-fetoprotein(AFP) elevated over normal range
                  constantly when hepatitis activity was restrained, and the case of suitable on
                  hepatocellular carcinoma on over in two more the above image diagnoses

        Exclusion Criteria:

          -  Unsuitable on inclusion criteria

          -  Patient who has had systemic anticancer therapy before (including sorafenib)

          -  Patient who is receiving another treatment to hepatocellular carcinoma recent 3 weeks
             (allow to local treatment of metastasis lesion only)

          -  Pregnant or Breastfeeding

          -  Urea cream contraindication patient (Acute eczema, Inflammatory dermatopathy and
             Hypersensitivity on Urea and Methylparaben)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Hoon Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Hoon Kim, MD</last_name>
    <phone>82-2-2626-3011</phone>
    <email>kjhhepar@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seung-hoe Song, MBE</last_name>
    <phone>82-2-2626-1635</phone>
    <email>ssessong@korea.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-hoe Song, MBE</last_name>
      <phone>82-2-2626-1635</phone>
      <email>ssessong@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Da-in Lee</last_name>
      <phone>82-2-2626-2279</phone>
      <email>0124dain@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109.</citation>
    <PMID>15466206</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.</citation>
    <PMID>21374666</PMID>
  </reference>
  <reference>
    <citation>Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176-86. doi: 10.1080/02841860701765675. Review.</citation>
    <PMID>18210295</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Zhou Q, Ma L, Wu Z, Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol. 2011 Jun;36(4):344-50. doi: 10.1111/j.1365-2230.2011.04060.x. Epub 2011 Apr 20. Review.</citation>
    <PMID>21507035</PMID>
  </reference>
  <reference>
    <citation>Iijima M, Fukino K, Adachi M, Tsukamoto T, Murai M, Naito S, Minami H, Furuse J, Akaza H. Sorafenib-associated hand-foot syndrome in Japanese patients. J Dermatol. 2011 Mar;38(3):261-6. doi: 10.1111/j.1346-8138.2010.01059.x. Epub 2010 Nov 2. Review.</citation>
    <PMID>21342228</PMID>
  </reference>
  <reference>
    <citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.</citation>
    <PMID>19095497</PMID>
  </reference>
  <reference>
    <citation>Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Guo X, Ye SL. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015 Mar 10;33(8):894-900. doi: 10.1200/JCO.2013.52.9651. Epub 2015 Feb 9.</citation>
    <PMID>25667293</PMID>
  </reference>
  <reference>
    <citation>Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8. Review.</citation>
    <PMID>18779536</PMID>
  </reference>
  <reference>
    <citation>Anderson RT, Keating KN, Doll HA, Camacho F. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist. 2015 Jul;20(7):831-8. doi: 10.1634/theoncologist.2014-0219. Epub 2015 Jun 17.</citation>
    <PMID>26084809</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Ji Hoon Kim</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Urea Cream</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

